Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.83 |
| ▸ | ATP1A1 | P05023 | 6/20 | 0.83 |
| ▸ | ATP1B1 | P05026 | 6/20 | 0.83 |
| ▸ | ATP1B2 | P14415 | 6/20 | 0.83 |
| ▸ | ATP1A2 | P50993 | 6/20 | 0.83 |
| ▸ | ATP1B3 | P54709 | 6/20 | 0.83 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.83 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.83 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 4/20 | 0.83 |
| ▸ | RAB9A | P51151 | 3/20 | 0.83 |
| ▸ | NPC1 | O15118 | 2/20 | 0.83 |
| ▸ | STAT3 | P40763 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | SLCO4C1 | Q6ZQN7 | 1/20 | 0.83 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gitoxin SCHEMBL27272378 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL12556684 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL25639501 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL29691433 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL18947800 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL30883086 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL14648721 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL18364705 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL20582695 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 | |
| Gitoxin SCHEMBL27272388 | 1.00 | TP53 (0.83) | TP53ATP1A1ATP1B1ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 829 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120084902-A | Biomarker for predicting colchicine preventive response of gout patient and application thereof | 查理高特(青岛)健康科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2024-07-04 | — | — | US | claimed |
| WO-2023239747-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230181610-A1 | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2023-06-15 | — | — | US | claimed |
| CN-114555104-A | Herbal preparation for stimulating hair growth, controlling hair loss, dandruff and infections thereof using ageratum species | GE营养有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-10624917-B2 | Compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss | YALE UNIVERSITY (US) | 2020-04-21 | — | — | US | claimed |
| EP-3021848-B1 | TREATMENT FOR MELANOMA | UNIV TEXAS (US) | 2018-08-22 | — | — | EP | claimed |
| US-20170232027-A1 | NOVEL COMPOSITIONS AND METHODS USEFUL FOR TREATING OR PREVENTING LIVER DISEASES OR DISORDERS, AND PROMOTING WEIGHT LOSS | UNIV YALE (US) | 2017-08-17 | — | — | US | claimed |
| EP-3182979-A1 | NOVEL COMPOSITIONS AND METHODS USEFUL FOR TREATING OR PREVENTING LIVER DISEASES OR DISORDERS, AND PROMOTING WEIGHT LOSS | Yale University (US) | 2017-06-28 | — | — | EP | claimed |
| EP-0941733-A2 | Methods of inhibiting leaderless protein export using cardiac glycosides and derivatives | The Scripps Research Institute (US) | 1999-09-15 | — | — | EP | claimed |
| EP-0828497-B1 | METHODS OF INHIBITING LEADERLESS PROTEIN EXPORT USING CARDIAC GLYCOSIDES OR AGLYCONES THEREFROM AND DERIVATIVES | SCRIPPS RESEARCH INST (US) | 1999-09-01 | — | — | EP | claimed |
| US-5891855-A | CONTACTING WITH CARDIAC GLYCOSIDE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-04-06 | — | — | US | claimed |
| EP-0828497-A1 | METHODS OF INHIBITING LEADERLESS PROTEIN EXPORT USING CARDIAC GLYCOSIDES OR AGLYCONES THEREFROM AND DERIVATIVES | The Scripps Research Institute (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1997028808-A1 | METHODS OF INHIBITING LEADERLESS PROTEIN EXPORT USING CARDIAC GLYCOSIDES OR AGLYCONES THEREFROM AND DERIVATIVES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-08-14 | — | — | WO | claimed |
| US-5053497-A | Phospholipid conjugates and their preparation | TECHNION INSTRUMENTS CORPORATION (US) | 1991-10-01 | — | — | US | claimed |
| EP-0187022-B1 | PHOSPHOLIPID CONJUGATES AND THEIR PREPARATION | TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation) (US) | 1991-05-29 | — | — | EP | claimed |
| EP-0187022-A2 | Phospholipid conjugates and their preparation | TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation) (US) | 1986-07-09 | — | — | EP | claimed |
| EP-0056995-B1 | CHEMICAL COMPLEX | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-03-26 | — | — | EP | claimed |
| EP-0056995-A1 | Chemical complex | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-08-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | SLC5A1, CFTR, SLC5A2 | TP53 3341/4885ATP1A1 4/4885ATP1B1 20/4885 |
| US-20230181610-A1 | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations | SLC5A1, CFTR, SLC5A2 | TP53 2670/4885ATP1A1 4/4885ATP1B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.